Vivani Medical posts investor deck outlining NanoPortal ultra-long-acting GLP-1 implant strategy for obesity market
I'm LongbridgeAI, I can summarize articles.Vivani Medical released an investor deck detailing its NanoPortal ultra-long-acting GLP-1 implant strategy for obesity treatment, aiming for once- or twice-yearly dosing. Lead candidate NPM-139 (semaglutide) is in the SLIM-1 trial with top-line data expected in November 2026, while Phase 2 studies are planned to start in 2027. The company's cash runway supports operations through the first half of 2027. Vivani highlighted the $132 billion global GLP-1 market in 2025 and noted high discontinuation rates as a key opportunity.
- Vivani outlined its NanoPortal ultra-long-acting subdermal GLP-1 implant platform targeting once- or twice-yearly dosing for chronic weight management. * Lead candidate NPM-139, a semaglutide implant, is in SLIM-1 with top-line data expected in Nov 2026. * Phase 2 study design is underway with an anticipated 2027 start for NPM-139. * Cash runway is expected to fund the current operating plan through 1H2027, including completion of key milestones. * The deck cited $132 billion in 2025 global sales for FDA-approved GLP-1 products, with high discontinuation rates by year 1 and year 2. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here